January 22, 2021

Adhesion Barrier Market is Eyeing to Generate Revenue at Steady Growth Rate in Near Future

What This Report Will Provide? This study involved four major activities in estimating the current size of the adhesion barrier market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth: [203 Pages Report] The global adhesion barrier market size is projected to reach USD 769 million by 2025 from USD 529 million in 2020, at a CAGR of 7.8%.

Major Growth Boosters: The increasing volume of surgeries and sports-related injuries, rising geriatric population, and the increasing awareness about adhesion formation and adhesion-related diseases are the major factors driving the growth of this market. However, currently, due to the COVID-19 pandemic, this market is witnessing a slight dip in its growth rate as a result of the decrease in the number of surgical procedures performed to safeguard patients. But the normalization of the global economy will slowly increase the surgical procedures kept on hold. This will, in turn, lead to a growth in the demand for biosurgery products from the last quarter of 2020 across North America and Europe, and from the first quarter of 2021 across the rest of the world.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=208132543

Recent Developments:

In December 2019, Baxter’s decision to acquire the Seprafilm adhesion barrier and related assets from Sanofi, which is one of the top players in this market, complemented its hemostat and sealant portfolio and strengthened the company’s presence in this market.

In October 2018, FzioMed launched the Oxiplex/IU Intrauterine Adhesion Barrier gel.

In December 2017, BD acquired C.R.Bard;this acquisition enabled the companies to combine their resources and position themselves as leaders in the global medical device technology industry, including the adhesion barriers market.

Key Questions Addressed in The Report: 1. Who are the top 10 players operating in the global adhesion barriers market?
2. What are the drivers, restraints, opportunities, and challenges in the adhesion barriers Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of adhesion barriers in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Regional Growth Analysis: The adhesion barrier market, by region, is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific is the most lucrative healthcare market, owing to its large population and growing healthcare sector. With a large and growing population in countries like China and India, the overall disease prevalence is also rising at an alarming rate in this region. The rapidly growing geriatric population, epidemiological shift from infectious to chronic diseases, increased life expectancy, the expansion of private-sector hospitals in rural areas, and the increased demand for surgical interventions are driving the demand for better healthcare facilities, medical devices, and technologies in the region.

Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=208132543

Key Players: Baxter International (US), Johnson & Johnson (J&J) (US), and Becton, Dickinson and Company (US), Integra LifeSciences (US), Anika Therapeutics (US), Atrium Medical Corporation (US), FzioMed (US), MAST Biosurgery (Switzerland), Innocoll (Ireland), Betatech Medical (Turkey), CorMatrix Cardiovascular, Inc. (US), Terumo Corporation (Japan), BiosCompass (US), W.L.Gore & Associates (US), and Allosource (US).